Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

AI Insight

Aficamten is a novel cardiac myosin inhibitor being investigated for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). This study examines the efficacy and safety of aficamten in patients with HCM who do not have left ventricular outflow tract obstruction but still experience significant symptoms. The trial evaluates whether aficamten can improve exercise capacity and reduce symptoms in this patient population that has limited treatment options.

Why it matters

Nonobstructive HCM affects approximately two-thirds of HCM patients and currently lacks specific approved therapies targeting the underlying disease mechanism. If effective, aficamten could provide a targeted treatment option for a large population of symptomatic HCM patients who previously had only symptom management available, potentially improving quality of life and functional capacity.